Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA in New-Onset Type 1 Diabetes.

Haller MJ, Schatz DA, Skyler JS, Krischer JP, Bundy BN, Miller JL, Atkinson MA, Becker DJ, Baidal D, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Herold KC, Marks JB, Moran A, Rodriguez H, Russell W, Wilson DM, Greenbaum CJ, Type 1 Diabetes TrialNet ATG-GCSF Study Group
Diabetes Care. 2018 41 (9): 1917-1925

PMID: 30012675 · PMCID: PMC6105329 · DOI:10.2337/dc18-0494

MeSH Terms (20)

Adolescent Adult Antilymphocyte Serum C-Peptide Child Cytoprotection Diabetes Mellitus, Type 1 Dose-Response Relationship, Drug Double-Blind Method Drug Therapy, Combination Female Glycated Hemoglobin A Granulocyte Colony-Stimulating Factor Humans Insulin-Secreting Cells Male Pilot Projects Polyethylene Glycols Recombinant Proteins Young Adult

Connections (1)

This publication is referenced by other Labnodes entities:

Links